About 23andMe Holding Co.
23andMe is a biotech company specialising in the fields of genomics and genetic testing. It offers direct-to-consumer (DTC) tests to the public, where a saliva sample will generate reports about genetic health risks, ancestral origins, carrier conditions, and predispositions to a wide range of ailments. The company was founded in 2006 and has headquarters in California. 23andMe also focuses on developing therapeutic medicines and drugs to improve the quality of patients’ lives, relating to oncology, immunology, and cardiovascular diseases. It has sold over 12 million DNA kits worldwide since its inception and has over 55 FDA-approved types of health reports. 23andMe stock listed on the Nasdaq exchange in June 2021 after merging with Richard Branson’s SPAC, VF Acquisition Corp. Start spread betting or trading CFDs on our 23andMe share price.
Why 300,000 committed global clients† choose CMC
-
Tax-free profits on spread bets. No stamp duty on CFDs^
-
Access to 12,000+ financial instruments
-
99.95%+ platform stability**
-
99.9% fill rate with 0.0029s execution*
-
London-Based Client Support
Constituent weightings
Component |
Weighting |
1 Day |
1 Month |
3 Month |
Trading hours
(shown in London local time )